Tenderwize
Back to tender search

Conclusion of non-exclusive drug discount agreement per §130a(8) SGB V via Open-House model for active substance lanthanum carbonate, chewable tablets

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2028 · 709 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lanthan(III)carbonat in der Darreichungsform Kautabletten

25/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

25 / 100

Complexity

20 / 100

Risk factors

No guaranteed minimum purchase quantities; volumes depend on prescribing and dispensing patterns. The buyer explicitly...

The buyer reserves the right to terminate the Open-House procedure early if exclusive discount agreements are signed. T...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclusion of non-exclusive drug discount agreements for lanthanum carbonate chewable tablets.
  • No exclusivity; multiple pharmaceutical entrepreneurs can be contracted simultaneously.
Show full summary

This is an Open-House model for concluding non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substance lanthanum carbonate in chewable tablet form (ATC V03AE03). The procedure is open to all pharmaceutical entrepreneurs meeting the requirements, with no exclusivity or guaranteed purchase volumes. The agreement runs until 31 July 2028. The notice explicitly states it is not a public procurement under Directive 2014/24/EU but is published for transparency; the 'open procedure' designation is for technical reasons only.

Risks

No guaranteed minimum purchase quantities; volumes depend on prescribing and dispensing patterns. The buyer explicitly...

The buyer reserves the right to terminate the Open-House procedure early if exclusive discount agreements are signed. T...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered drugs.

Eligibility

  • Must submit declaration of no exclusion grounds per §§123, 124 GWB.

Administrative

  • Must submit declaration regarding Russia sanctions per EU Regulation 833/2014.

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria specified as this is an Open-House model without competition.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Conclusion of non-exclusive drug discount agreement per §130a(8) SGB V via Open-House model for active substance lanthanum carbonate, chewable tablets

Single lot covering the Open-House model for lanthanum carbonate chewable tablets. No estimated value, no minimum quantities. The agreement is non-exclusive and available to all qualified pharmaceutical entrepreneurs.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jul 2026 - Jul 2028

Category

Pharmaceutical products

Award Criteria

No award criteria specified as this is an Open-House model without competition.

Deadline

Expired Jul 07, 2026

Procurement Details

Publication date
19 May 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
344198-2026

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3